Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Humana Inc (HUM) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance

Humana IncTrade
Schwab US Dividend Equity ETFTrade

Price performance (Past 24H)

Key statistics

Humana Inc vs Schwab US Dividend Equity ETF — how do they compare? Humana Inc trades at $444.98 (market cap $47.61B), while Schwab US Dividend Equity ETF trades at $33.1 (market cap $108.68B). The key difference: Schwab US Dividend Equity ETF is far larger — about 2.3× Humana Inc's market cap, and Humana Inc pays a 0.89% dividend while Schwab US Dividend Equity ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Schwab US Dividend Equity ETF for 62 Days on average.

HUMSCHD
Market Cap
$47.61B$108.68B
Volume
1,827,33221,463,071
Sector
HealthBroad Market / Factor
52-Week High
$409.85$35.21
52-Week Low
$163.67$26.44
Typical Hold Time
53 Days62 Days
Enterprise Value
$54.97B—
Dividend Yield
0.89%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Humana Inc

Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.

Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.

Schwab US Dividend Equity ETF

SCHD trades at $32.65, down 0.61% on the day, with a bearish technical signal driven by moving averages. The ETF has outperformed the S&P 500 in 2026, with dividend growth attracting income investors. Recent news highlights its defensive tilt and quality focus amid a market pullback.

Outlook is mixed: strong dividend appeal and low fees support long-term income, but technical weakness and interest rate sensitivity pose near-term risks. Investors should weigh SCHD's consistent payout growth against potential underperformance in rising rate environments.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HUM

No sentiment data available yet.

SCHD
82% Buy18% Sell
Avg holding period · 62 Days

Top news

Latest headlines on both assets

About Humana Inc

Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Read more on HUM →

About Schwab US Dividend Equity ETF

SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.

Read more on SCHD →